-A-     -B-     -C-     -D-     -E-     -F-     -G-     -H-     -J-     -K-

-L-     -M-     -N-     -O-     -P-     -R-     -S-     -T-     -U-     -W-

 

-A-

 

Dan Aistrope, Pharm. D.; Clinical Assistant Professor; Division of Pharmacy Practice & Administration

 

Lynn Anliker, Pharm.D.; Clinical Assistant Professor; Division of Pharmacy Practice & Administration

  • Cardiovascular medicine – antiplatelets, atrial fibrillation, cardiothoracic surgery, and others
  • Critical care medicine
  • Pharmacokinetic modeling

-B-

 

Mostafa Badr, Ph.D.; Professor; Division of Pharmacology & Toxicology
The major focus of research activities in Dr. Badr’s laboratory is on the investigation of molecular and biochemical mechanisms whereby various therapeutic agents and industrial chemicals cause non-genotoxic liver cancer, as well as modulate immunity and inflammatory responses. Roles of aging, metabolic diseases (diabetes) and nutrients in these processes are characterized using biochemical and molecular biological techniques.

 

Hari K. Bhat, Ph.D.; Associate Professor; Pharmacology & Toxicology
Dr. Bhat’s research interests focus on the elucidation of biochemical and molecular mechanisms of

  • hormonal breast carcinogenesis
  • breast cancer chemoprevention using phytoestrogens
  • endocrine disruptors
  • unequal burden of breast cancer among minority population

The mechanisms of hormonal breast carcinogenesis are being investigated using animal models, relevant cell lines and human tissue samples.

 

Wayne M. Brown, Ph.D.; Associate Professor; Pharmacy Practice & Administration
Improving care in hospitals and long-term care facilities

 

Angela Brownfield, Pharm.D.; Assistant Director Of Experiential Learning, Satellite Pharm.D. Program, Division of Pharmacy Practice & Administration

 

Patrick J. Bryant, Pharm.D., FSCIP; Clinical Professor, Pharmacy Practice & Administration

  • Evidence Based Medicine
  • Methods/processes involved
  • Trial Designs/evaluation methods
  • Biostatistical Interpretation of results and tests used
  • Teaching methods
  • Drug Information
  • Technology use
  • Teaching methods
  • Competitive Intelligence
  • Competitive technical intelligence
  • Competitive business intelligence

Andrew Bzowyckyj, Pharm.D.; Clinical Assistant Professor; Division of Pharmacy Practice & Administration

 

-C-

 

Kun Cheng, Ph.D.; Assistant Professor; Pharmaceutical Sciences

  • Development of gene therapy for breast cancer, prostate cancer, liver fibrosis, and islet transplantation
  • Identification of molecular ligand for specific cell types
  • Development of targeted delivery system for therapeutic macromolecules
  • Synthesis of novel polymer for gene drug delivery
  • Designing of pro-drug for improving target-ability and efficiency

Kelly A. Cochran, Pharm.D., BCPS; Clinical Assistant Professor; Pharmacy Practice & Administration
Anticoagulation, Chronic Diseases, Adverse Drug Events, Quality Improvement, Patient Centered Medical Home, Rural Health education, Fostering a sense of community among students across distance locations

 

-D-

 

Kristen DiDonato, Pharm.D.; Clinical Assistant Professor; Department of Pharmacy Practice & Administration
Health and wellness, immunizations, innovative community pharmacy services

 

-E-

 

-F-

 

Simon H. Friedman, Ph.D.; Associate Professor; Pharmaceutical Sciences
Bioorganic Chemistry/Chemical Biology: Control of gene expression, structure based ligand design, molecular recognition. Targeting of nucleic acid/protein interfaces. Fundamental issues of ligand/receptor binding energetics. Design, synthesis and testing of therapeutic molecules. Molecular evolution.

 

-G-

 

Linda Garavalia, Ph.D., Professor and Associate Dean for Academic Affairs; Pharmacy Practice & Administration
Classroom learning among college students, Behaviors related to medication adherence in heart patients

 

Maqual Graham, Pharm.D.; Associate Professor; Division of Pharmacy Practice & Administration

 

William G. Gutheil, Ph.D.; Associate Professor; Division of Pharmaceutical Sciences:

  • Enzymology of the Penicillin-Binding Proteins (PBPs) and Development of New Antibacterial Agents
  • Hierarchical Interaction Based Analysis of Complex Thermodynamic Systems
  • Glutathione-Dependant Formaldehyde Dehydrogenases (Inactive)
  • Numerical Modeling Complex Kinetic Systems (Inactive)

 

-H-

 

Jeremy Hampton, Pharm.D.; Clinical Assistant Professor; Division of Pharmacy Practice & Administration
Study Coordinator: Strategies using off-patent antibiotics for community-acquired methicillin-resistant Staphylococcus aureus (“Stop MRSA” ) Investigator: “Heparin in Anaphylaxis”

 

Karen Hardinger, Pharm.D., BCPS; Clinical Associate Professor, Pharmacy Practice & Administration
Efficacy of immunosuppressants, kidney transplantation outcomes, viral infections in transplantation, adverse drug reactions of immunosuppressants, pharmacokinetics of immunosuppressive medications, adherence in transplantation


-I-

 

Orisa J. Igwe, Ph. D; R.Ph.; Associate Professor; Pharmacology & Toxicology

  • Understanding the fundamental mechanisms that underlie the hyperalgesic or allodynic states, which characterize chronic inflammatory or neuropathic pain states
  • Defining the role of phospholipids/Ca2+ pathways in neuronal transmission deficits associated with aging

 

-J-

 

Thomas P. Johnston, Ph.D., R.Ph.; Professor; Pharmaceutical Sciences
An active area of research in the Johnston laboratory consists of the delivery of biologically-active small peptide drugs via the paracellular route following oral dosing. On a totally different front, we have developed a mouse model of dyslipidemia and atherosclerosis and are presently determining convenient biomarkers (oxidized-LDL-cholesterol, cell adhesion molecules, PPARs, “dysfunctional” HDL-cholesterol, etc.) that may be used to predict patients at risk for future coronary artery disease.

 

-K-

 

Maureen E. Knell, Pharm.D., BCPS; Clinical Associate Professor; Pharmacy Practice & Administration
Chronic pain management, interprofessional education, scholarship of education, Medicare Part D, arthritis, dietary supplement use, other ambulatory care/internal medicine areas.

 

Peggy G. Kuehl, Pharm.D., FCCP, BCPS; Community Pharmacy Practice Coordinator; Clinical Associate Professor; Pharmacy Practice & Administration
Documentation of sustainable non-dispensing patient care services in community settings

 

Anil Kumar, Ph.D.; Chair and Professor; Pharmacology & Toxicology

  • Effect of drug and alcohol abuse on pathogenesis of AIDS
  • Identification of target of immune responses in HIV-1 during natural infection
  • Compartmentalization of HIV during natural infection
  • Vaccine approaches in monkey model of AIDS

Santosh Kumar, Ph.D.; Assistant Professor; Pharmacology & Toxicology

  • Engineering mammalian cytochromes P450 to study structure-functions and design as biocatalysts
  • Interactions between ARV therapy and substance of abuse

 

-L-

 

Chi H. Lee, Ph.D.; Professor; Pharmaceutical Sciences

  • Working on the formulation development for prevention against sexually transmitted disease including AIDS and cancer onset
  • Working on the calcium related regulation and the role of proteins in the area of fertility control, cardiovascular and skin diseases

 

Cameron C. Lindsey, Pharm.D., BC-ADM; Professor; Pharmacy Practice & Administration
Diabetes, cardiovascular risk reduction & public health

 

Yifei (Efay) Liu, B.S.-Pharm., Ph.D.; Assistant Professor; Pharmacy Practice & Administration

  • Behaviors of patients or health providers in the health care system, including (1) the application of the Theory of Planned Behavior, (2) the collaboration between pharmacists and other health providers, (3) patients’ medication adherence, and (4) patients’ search for health information
  • Marketing activities in the health care system, including (1) the implementation, marketing, and evaluation of pharmacy services, (2) the impact of direct-to-consumer advertising of prescription drugs, and (3) the marketing channels of pharmaceuticals
  • Patients’ health outcomes, including (1) the cause or impact of drug-related problems, and (2) maternal and child health outcomes.

 

-M-

 

Patricia A. Marken, Pharm.D., FCCP, BCPP; Professor and Associate Dean for Student Affairs; Pharmacy Practice & Administration and Psychiatry
Pharmacy education, programmatic assessment, curricular design, health information technology

 

Cydney McQueen, Pharm.D.; Clinical Associate Professor; Division of Pharmacy Practice & Administration

 

Tatum Mead, Pharm.D.; Clinical Assistant Professor; Division of Pharmacy Practice and Administration

 

Russell B. Melchert, Ph.D., R.Ph.; Dean, UMKC School of Pharmacy

 

Ashim K. Mitra, Ph.D.; Chair and Professor; Pharmaceutical Sciences
Delivery and targeting of antiviral agents and development of noninvasive delivery systems for peptide and protein drugs.

 

Mridul Mukherji, D.Phil.; Assistant Professor; Division of Pharmaceutical Sciences

 

-N-

 

Leigh Anne Nelson, Pharm.D., BCPP; Associate Professor; Pharmacy Practice & Administration
Antipsychotic use and Schizophrenia

 

-O-

 

Lauren Odum, Pharm.D., BCPS; Clinical Assistant Professor; UMKC School of Pharmacy at MU
Cardiovascular risk reduction topics, particularly hypertension, resistant hypertension, anticoagulation, and smoking cessation

 

Erica Ottis, Pharm.D.; Clinical Assistant Professor; Division of Pharmacy Practice and Administration
Assessment, Simulation-Based Learning in Pharmacy Education, Objective Structured Clinical Examinations, and Chronic Obstructive Pulmonary Disease

 

-P-

 

Heather Pace, Pharm.D.; Assistant Director, Drug Information Center; Clinical Associate Professor

 

Mark E. Patterson, Ph.D., M.P.H.; Assistant Professor of Pharmacy Practice and Administration

  • Health information technology systems and quality of care: How do clinical decision support systems impact hospital prescribing patterns and patient medication adherence?
  • Organizational factors influencing medical error reporting: Which aspects of patient safety culture impacts medical error reporting rates within hospitals?
  • Pharmaceutical policies impacting patient safety and access to care: How do Federal Drug and Administration policies impact medication innovation?

 

-R-

 

Rafia S. Rasu, PhD; Associate Professor; Pharmacy Practice & Administration

  • Outcomes Research
  • Health Services Research
  • Pharmacoeconomics
  • Pharmacoepidemiology
  • Economic Evaluation of Health Care

 

Valerie Ruehter, Pharm.D., BCPP; Clinical Assistant Professor and Director of Experiential Learning; Division of Pharmacy Practice and Administration

 

-S-

 

Jennifer Santee, Pharm.D.; Clinical Associate Professor; Division of Pharmacy Practice & Administration

 

Stephanie M. Schauner, Pharm.D., BCPS; Clinical Assistant Professor; Pharmacy Practice & Administration
My research interests involve family medicine practices such as adult and adolescent immunizations, diabetes, anticoagulation and contraception.

 

Mark Sawkin, Pharm.D.; Clinical Assistant Professor; Division of Pharmacy Practice and Administration

 

Peter Silverstein, Research Associate Professor, Division of Pharmacology and Toxicology
HIV/AIDS

 

Roger Sommi, Pharm.D., FCCP, BCPP; Professor of Pharmacy Practice & Administration and Psychiatry

 

Andrew J. Smith, Pharm.D., BCPS; Clinical Assistant Professor; Pharmacy Practice & Administration

  • Anti-platelet medication adherence
  • Technology in teaching

 

Morgan Sperry, Pharm. D.; Assistant Director, Drug Information Center; Clinical Assistant Professor

 

Steve Stoner, Pharm.D., BCPP; Chair and Clinical Professor; Division of Pharmacy Practice and Administration

 

-T-

 

-U-

 

-W-

 

Jianping Wang, M.D., Ph.D.; Associate Professor; Pharmacology & Toxicology
Mounting evidence supports that cytokines are important in neuroimmune communication. This signaling interaction is involved in brain physiology and pathophysiology. As the prime innate immune mediators, interferons (IFNs) have been found in association with depression, anxiety, schizophrenia, and etc. To understand the roles of these pleiotropic endogenous molecules in the eitopathogensis of clinical illnesses, we have been working on establishing animal model for the relevant clinical conditions and elucidating the molecular entity by employing integrated behavioral, pathological, pharmacological, molecular and genetic approaches. We found that these anti-viral cytokines are double-edged swords that are not only essential for host defense against various infections, but also implicated in pathogenesis of several CNS diseases.

 

Beth Winans, PharmD, BCPP; Clinical Associate Professor; Pharmacy Practice & Administration
Schizophrenia & mood disorders

 

Eric Wombwell, Pharm.D., BCPS; Clinical Assistant Professor; Division of Pharmacy Practice and Administration

  • Education based technology and the impact on learning outcomes
  • Pharmacy leadership
  • Residency expansion
  • Emerging and reemerging infectious pathogens